GeneNews Limited
TSX : GEN

GeneNews Limited

July 15, 2011 08:12 ET

Sentinel Principle® Used to Discover Blood Based Biomarkers to Predict Risk of Liver Cancer from Patients With Chronic Hepatitis

TORONTO, ONTARIO--(Marketwire - July 15, 2011) - GeneNews Limited (TSX:GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that a poster entitled "Biomarkers to predict risk of subsequent hepatocellular cancer in patients with chronic hepatitis" describing the initial phase of analysis of its 1,600-cohort study was presented by Dr. Haniza Omar today at the 9th Liver Update 2011 conference being held at the Sunway Resort Hotel & Spa in Petaling Jaya, Selangor, Malaysia from July 13-17.

The poster reports on the application of GeneNews' proprietary Sentinel Principle® platform technology to a subset of the 1,169 Malaysian blood samples, collected to date, representing matched patients suffering from hepatocellular carcinoma ("HCC"), chronic hepatitis B ("HPB") patients and healthy controls. The Sentinel Principle® is based on the concept that all clinical conditions and body states, including those resulting from disease or in response to treatment, generate characteristic gene expression signatures in the blood as a result of the close physiological interaction of blood with the cells, tissues and organs of the human body. This technology is the basis of GeneNews' first product, ColonSentry™, the world's first blood test for colorectal cancer.

The poster concludes that the biomarker panel was able to identify a blood-based gene expression biomarker signature that is prognostic for later development of HCC in patients with HPB. Functional analysis indicated that the biomarker genes identified are involved in transcription, apoptosis, signal transduction, cell cycle, as well as inflammation and angiogenesis.

In June 2010, the Company's Malaysian subsidiary entered into a Strategic Alliance with the Malaysian Ministry of Health for this project which aims to identify blood-based cancer biomarkers which, if further developed, can allow for early identification of HCC in a high risk population.

"HCC is a disease with poor prognosis and high mortality," said Gailina J. Liew, President and Chief Operating Officer of GeneNews. "This study identifies gene expression biomarker models which can be used for subclinical detection of HCC, potentially improving prognosis of this devastating disease."

About GeneNews

GeneNews is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews launched its first commercial product, ColonSentry™, a blood-based test to pre-screen and assess an individual's risk for colorectal cancer, in Canada in 2008. The company's marketing partners, GeneDiagnostics and Enzo Clinical Labs, are expected to launch the ColonSentry™ test in China and the United States in 2011. For more information on GeneNews and ColonSentry™, visit www.genenews.com or www.ColonSentry.com.

Forward-Looking Statements

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

Contact Information